1. The economic burden of coronary artery disease: A systematic review
- Author
-
P Lanza-León, L Sánchez-Ruiz, D Cantarero-Prieto, C Blázquez-Fernández, P Moreno-Mencía, F Pérez-Hernández, JM de la Torre, and J Cayón-de las Cuevas
- Subjects
Public Health, Environmental and Occupational Health - Abstract
Background Although mortality has decreased in recent decades and patient survival rates have increased, cardiovascular disease remains one of the leading causes of mortality and morbidity in developed countries these days. The purpose of this study is to analyze the available literature that describes the economic burden of coronary artery disease and to compare costs. The study is framed in the Horizon 2020 project “A patient-centered early risk prediction, prevention, and intervention platform to support the continuum of care in coronary artery disease (CAD) using eHealth and artificial intelligence - TIMELY”. Methods A systematic literature review has been carried out using various databases such as PubMed, Web of Science, Cochrane Library and Scopus. Precisely, a 5-year retrospective horizon has been considered until the present (April 2021). In all databases, terms related to “Coronary artery disease” and “Cost*” were combined. Results 113 publications were primary located. After examining the titles based on the eligibility criteria, 16 articles were selected. Of these, 5 articles were excluded because they did not meet the inclusion criteria. Therefore, a final set of 11 selected studies were considered in this review. The costs included in the review correspond, mainly, to direct healthcare costs. Our results affirm that the highest costs are derived from the possible adverse effects (€41,450, approx.). Conclusions The figures presented in this literature review will provide a good framework to quantify these costs for both economic experts and researchers and political decision-makers, both nationally and internationally. Key messages The costs included in the review correspond, mainly, to direct healthcare costs. The highest costs are derived from the possible adverse effects.
- Published
- 2021
- Full Text
- View/download PDF